Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otenaproxesul pulled as Arthritis drug.

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Oct 14, 2021 6:43pm

196 Views

Post# 34007257

RE:RE:RE:RE:RE:Otenaproxesul pulled as Arthritis drug.

I agree with everything you say. But why did you stay invest here because there are certain people who disappear on these type of days that may or may not be paid by this company to say things to lead us on and take no responsibilty

Nick80 wrote: Thats what I dont understand either I would like someone of antibe to take position to those findings...

If they don't buy their stock to show their confiction than I don't know what could really bring some trust for investors... other than some magic which i suppose will take years

Imagine this elevation occuring on the shorter term for the 'acute pain' than either the previous data is suspecious or their is anther underlying issue for a specific group of people...

Pretty upset with this investment and how everything panned out... I felt not very convinced by Dan's presentations from the beginning should have listened to my intuition and take my investment when it was still in the green...